🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementDizziness and orthostatic hypotension on GLP-1 — March 2026

Dizziness and orthostatic hypotension on GLP-1 — March 2026

laura_annarbor Sat, Feb 22, 2025 at 11:09 AM 14 replies 1,814 viewsPage 1 of 3
This thread is more than 15 months old. Information may be outdated. Consider searching for more recent discussions.
laura_annarbor
Member
189
890
Dec 2024
Ann Arbor, MI
Feb 22, 2025 at 11:09 AM#1

Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

What I am trying to establish is whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out.

Happy to be told the question itself is wrong.

8 3labquiet_amy, emily_PDX, Dr.SleepRoch and 5 others
Reply Quote Save Share Report
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
Feb 22, 2025 at 12:01 PM#2

Answering the narrow version, because the broad one does not have a single answer. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

7 2Dr.DermMIA, fiona_VT, denise_HTX and 4 others
Reply Quote Save Share Report
denise_HTX
Member
145
678
Jan 2025
Houston, TX
Feb 22, 2025 at 12:53 PM#3
DanielChem_CHI said:
The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the…

That is correct as far as it goes, and here is where it stops going. The meal advice is right and incomplete without the hydration point. People stop drinking because drinking makes them feel full, then attribute dehydration symptoms to the drug.

6 1JessicaH_TX, KevinCompounds, TirzTom and 3 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
DerekSJ_a1c
Member
378
1,678
Aug 2024
San Jose, CA
Feb 22, 2025 at 1:46 PM#4
laura_annarbor said:
Nausea arrived on day two of each dose step, lasted about four days, and disappeared entirely by the second week — until the step where it did not.

Same position here, arrived at the long way round. Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

Last edited: Feb 22, 2025 at 6:46 PM
5 0traveltech_sara, AttorneyGrant, DebRD_ATL and 2 others
Reply Quote Save Share Report
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Feb 22, 2025 at 6:44 PM#5

Adding the clinical framing, because it changes how the question reads. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

4 24emily_PDX, Dr.SleepRoch, laura_annarbor and 1 other
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register